Miami man pleads guilty to selling adulterated, misbranded HIV drugs across U.S.

Miami man pleads guilty to selling adulterated, misbranded HIV drugs across U.S.


A Miami man has pleaded guilty in federal court to distributing adulterated HIV drugs dispensed to U.S. patients.

Miami Herald | Tribune News Service | Getty Images

A Miami man pleaded guilty to distributing as much as $25 million worth of misbranded and adulterated HIV drugs that were dispensed by pharmacies across the U.S. to unsuspecting patients, federal prosecutors said.

Armando Herrera, 43, faces a maximum possible sentence of five years in prison for the crime.

Herrera pleaded guilty in U.S. District Court in Miami on Monday to one count of conspiracy to introduce adulterated and misbranded drugs in the U.S. market, court filings show.

A medication is adulterated if a substance has been substituted for the drug in whole or in part.

Herrera and his co-conspirators set up companies in Texas, California and Washington state that acquired large quantities of misbranded and adulterated HIV medication from legal channels, falsified the pills’ packaging and sold them at a steep discount to wholesalers that later sold them to pharmacies, court documents say.

Prosecutors said the wholesalers were involved in the criminal scheme, but the pharmacies were unaware that the drugs were altered or misbranded.

The adulterated and misbranded drugs included Truvada, Biktarvy and other unnamed medications.

Truvada is prescribed to prevent HIV infection in people who are at risk of contracting the virus. The medication is also used in combination with other drugs to treat infection.

Biktarvy is prescribed to treat HIV infection. Truvada and Biktarvy are manufactured by Gilead Sciences.

Herrera and his co-conspirators received between $16.7 million and $25 million in payment from two wholesalers, according to court filings.

The filings did not say how Herrera and his co-conspirators acquired the drugs.

Medications are often siphoned off the legal market by purchasing them from individual patients who were prescribed the drugs.

Herrera is scheduled to be sentenced Dec. 21. His lawyer did not immediately respond to CNBC’s request for comment.



Source

Here’s a rapid-fire update on what Trump will mean for all 33 portfolio stocks
Health

Here’s a rapid-fire update on what Trump will mean for all 33 portfolio stocks

Here’s a rapid-fire update on all the stocks in Jim Cramer’s Charitable Trust, the portfolio we use for the CNBC Investing Club. During the November Monthly Meeting on Thursday, Jim looked at how Donald Trump’s return to the White House could impact each company — good, bad or not much at all. Apple : If […]

Read More
Smart ring leader Oura plans international push as CEO touts new features and thinking on hardware
Health

Smart ring leader Oura plans international push as CEO touts new features and thinking on hardware

The Oura Ring 4 Courtesy: Oura LISBON — Samsung’s foray into smart rings isn’t concerning the boss of the product category’s pioneer, Oura — in fact, Tom Hale says he’s seeing a boost in business. “I’m sure that a major tech company making an announcement saying: ‘Hey, this is a category that matters. It’s going to be […]

Read More
Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy
Health

Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy

The office building of biopharmaceutical company AstraZeneca is being seen in Shanghai, China, on May 23, 2024.  Nurphoto | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. AstraZeneca said it is doubling down […]

Read More